Saikosaponin C exhibits anti-HBV activity, it has the potential for therapeutic angiogenesis but is not suitable for cancer therapy, it also might be a novel therapeutic tool for treating human AD and other neurodegenerative diseases. It inhibited caspase-3 activation and caspase-3-mediated-FAK degradation, induced matrix metalloproteinase-2 (MMP-2)、vascular endothelial growth factor (VEGF) 、the p42/p44 mitogen-activated protein kinase (MAPK, ERK). Saikosaponin C is a member of the class of saikosaponins that is saikogenin E substituted by a 6-deoxy-alpha-L-mannopyranosyl-(14)-[beta-D-glucopyranosyl-(16)]-beta-D-glucopyranosyl group at position 3beta. It is a natural product isolated from the traditional Chinese herb, Radix Bupleuri and exhibits anti-HBV replication activity. It has a role as an anti-HBV agent and a plant metabolite.